M G.Savad
2.3K posts

M G.Savad
@savadMG
Husband, Father, Son, MD, MSc, Radiation oncologist.🇨🇦
Ontario, Canada Katılım Nisan 2018
813 Takip Edilen527 Takipçiler
M G.Savad retweetledi

So, who is going to develop free software to overlay RT DICOM onto follow-up CT imaging after radiotherapy, thereby decreasing patient scanxiety by correlating prior radiotherapy fields w/ diagnostic imaging?
Because this paper shows why it matters.🧵👇
@uwradonc @UWRadiology

English
M G.Savad retweetledi

Something berry sweet is coming! Fields across Canada are gearing up for peak Strawberry season from May to July, making it the perfect excuse for a sweet spring outing. Which Canadian town do you get your strawberries from? #PickStrawberriesDay🍓🌞

English
M G.Savad retweetledi

Reminder for those with #ASTRO25 onDemand access:
If you purchased ASTRO 2025 full registration or the 2025 Meeting OnDemand, your access is expiring soon. You have until June 1, 2026, to view the content and claim your corresponding CME credits. Please contact ASTRO eLearning with any questions.
Log in and watch before it's gone: ow.ly/ztQi50YWEoV

English
M G.Savad retweetledi

Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study
buff.ly/7aeyobw
FASTRACK II, the first phase 2 trial of stereotactic ablative body radiotherapy☢️ (SABR) for primary renal cell carcinoma, evaluated long-term outcomes in non-surgical patients. Among 70 treated patients, SABR achieved 100% local control at 3, 5, and 7 years, with no local recurrences or cancer-related deaths. Treatment was well tolerated, with limited grade 3 toxicities and no grade 4 events or treatment-related deaths, supporting SABR as a safe, effective non-invasive option. #KidneyCancer #ESTRO26
@_ShankarSiva
@DocJarad
@FarshadForoudi
@DrMHofman
@declangmurphy
@lawrentschuk
@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72
Pinging OA faculty
@MKnoll_MD
@Icro_Meattini
@seanmmcbride
@NiuSanford
@to_be_elizabeth

English
M G.Savad retweetledi

@AggarwalOnc presents ARCHERY TRIAL at #ESTRO26; automated contouring/planning with AI.
- Globally recruiting, centrally reviewed in the UK
- 98% of cervical cancer plans were clinically acceptable
- >80% of #prostatecancer
👏🏽👏🏽Raising the bar for equity/access to #radiotherapy!



English
M G.Savad retweetledi

Ultra-Hipofx pélvico + BT prostática equitóxico (AGUDO) vs. Fraccionamiento convencional.
#ESTRO26
Piet Ost@piet_ost
🔬 PCS-XI phase III complete cohort (n=501): Pelvic ultra-hypofractionation (25Gy/5fx) combined with HDR brachytherapy boost shows comparable acute AEs and QoL to conventional fractionation in high-risk prostate cancer. #ESTRO26
Salamanca, Spain 🇪🇸 Español
M G.Savad retweetledi

#ESTRO26 - 📣 FASTRACKII final results, median F/U of 5 years. Thank you patients, funders, investigators - #kidneycancer #kcsm
1) 100% Local Control: No local recurrences were observed at 36, 60, or 84 months.
2) 100% Cancer-Specific Survival
3) Grade 3 AEs remain at 10%

English
M G.Savad retweetledi




















